Login to Your Account

Genmab Pays $240M for PDL's Antibody Manufacturing Facility

By Jennifer Boggs

Friday, February 22, 2008
Strengthening its position as a major antibody player, Genmab A/S said it is securing its own manufacturing capability in a deal to acquire troubled PDL BioPharma Inc.'s Brooklyn, Minn., facility for $240 million. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription